Search results for "PIP"

showing 10 items of 1156 documents

A Comparison of Five Maintenance Therapies for Reflux Esophagitis

1995

Patients with reflux esophagitis have a high rate of relapse within one year after therapy is discontinued.We enrolled 175 adults with endoscopy-confirmed reflux esophagitis in a prospective study comparing five maintenance therapies. All the patients were initially treated with omeprazole (40 mg orally once a day) for four to eight weeks, and healing was confirmed by endoscopy. Participants were then stratified according to their initial grade of esophagitis and randomly assigned to 12 months of treatment with one of the following: cisapride (10 mg three times a day), ranitidine (150 mg three times a day), omeprazole (20 mg per day), ranitidine plus cisapride (10 mg three times a day), or …

AdultMalemedicine.medical_specialtyRanitidineSeverity of Illness IndexGastroenterologyDisease-Free SurvivalRanitidinePiperidinesRecurrenceInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesReflux esophagitisProspective cohort studyEsophagitis PepticOmeprazoleCisapridemedicine.diagnostic_testEsophageal diseasebusiness.industryGeneral MedicineMiddle AgedAnti-Ulcer Agentsmedicine.diseaseSurgeryEndoscopyTreatment OutcomeHistamine H2 AntagonistsCisaprideDrug Therapy CombinationFemaleEsophagoscopybusinessEsophagitisOmeprazolemedicine.drugNew England Journal of Medicine
researchProduct

Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transp…

2019

Abstract Chronic graft-versus-host disease (cGVHD) remains the leading cause of late morbidity and mortality. Despite the growing number of treatment options in cGVHD, evidence remains sparse. The German-Austrian-Swiss GVHD Consortium performed a survey on clinical practice in treatment of cGVHD among transplant centers in Germany, Austria, and Switzerland in 2009 and 2018 and compared the results. The survey performed in 2009 contained 20 questions on first-line treatment and related issues and 4 questions on second-line scenarios followed by a survey on all systemic and topic treatment options known and applied, with 31 of 36 transplant centers (86%) responding. The survey in 2018 repeate…

AdultMalemedicine.medical_specialtyRuxolitinibMedizinBronchiolitis obliteransGraft vs Host DiseaseDiseasechemistry.chemical_compoundPiperidinesGermanyNitrilesmedicineHumansIntensive care medicineBronchiolitis ObliteransImmunosuppressive treatmentImmunosuppression TherapyTransplantationbusiness.industryAdenineHematopoietic Stem Cell TransplantationHematologymedicine.diseaseClinical trialGraft-versus-host diseasePyrimidineschemistryIbrutinibAustriaChronic DiseasePyrazolesFemaleAllogeneic hematopoietic stem cell transplantbusinessSwitzerlandmedicine.drugBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
researchProduct

Relaxation of the isolated human internal anal sphincter by sildenafil.

2007

Abstract Background Hypertonicity of the internal anal sphincter (IAS) appears to be involved in the pathogenesis of anal fissure. The relaxant effects of sildenafil, a selective phosphodiesterase 5 (PDE5) inhibitor, on isolated human IAS were investigated. Methods The efficacy (maximal effect, Emax) and potency (−log IC50, where IC50 is half-maximal inhibitory concentration) of the PDE5 inhibitors, sildenafil and zaprinast, and of nitric oxide donors, sodium nitroprusside and glyceryl trinitrate, as relaxants of histamine (0·1 mmol/l)-induced tone were examined in IAS strips under isometric contraction. The presence of PDE5 isoenzymes and changes in intracellular calcium and cyclic nucleot…

AdultMalemedicine.medical_specialtySildenafilPhosphodiesterase InhibitorsMuscle RelaxationAnal CanalIn Vitro TechniquesPiperazinesSildenafil CitrateInternal anal sphincterchemistry.chemical_compoundCyclic nucleotideInternal medicinemedicineHumansSulfonesCyclic GMPAgedAged 80 and overAnal fissureDose-Response Relationship Drugbusiness.industryMuscle SmoothMiddle Agedmedicine.diseaseMuscle relaxationEndocrinologychemistryPurinescGMP-specific phosphodiesterase type 5SurgeryFemaleSodium nitroprussideZaprinastbusinessmedicine.drugThe British journal of surgery
researchProduct

Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late ch…

2007

The introduction of Imatinib (IM) has significantly altered the treatment for CML, although only limited follow-up results are available. As failure of Interferon-alpha had been associated with poor prognosis and results of IM-treatment in this patient group may allow earlier estimation of long-term benefits for early chronic phase patients. Therefore we prospectively analyzed the quality and duration of remissions and the rate of BCR-ABL resistance mutations occurring in patients treated with IM, if they were intolerant or refractory to interferon. Fifty-nine patients were included and median follow up is 4.75 years. Haematologic remission rate was 92% and 62% of patients achieved at least…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classAntineoplastic AgentsBiologyGastroenterologyTyrosine-kinase inhibitorDisease-Free SurvivalPiperazinesMedian follow-upInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansProtein Kinase InhibitorsSurvival analysisAgedRetrospective StudiesHematologyImatinibHematologyMiddle Agedmedicine.diseaseSurvival AnalysisLeukemiaImatinib mesylatePyrimidinesImmunologyBenzamidesImatinib MesylateFemaleChronic myelogenous leukemiamedicine.drugAmerican journal of hematology
researchProduct

Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone p…

2018

BACKGROUND Long-acting injectable (LAI) antipsychotics can improve medication adherence and reduce hospitalisation rates compared with oral treatments. Paliperidone palmitate (PAL) and aripiprazole monohydrate (ARI) LAI treatments were associated with improvements in global functioning in patients with schizophrenia. OBJECTIVE The objective of this study was to assess the predictive factors of better overall functioning in patients with chronic schizophrenia and schizoaffective disorder treated with PAL and ARI. METHOD Enrolled were 143 (97 males, 46 females, mean age 38.24 years, SD = 12.65) patients with a diagnosis of schizophrenia or schizoaffective disorder, whom we allocated in two gr…

AdultMalemedicine.medical_specialtyaripiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; neurology; neurology (clinical); psychiatry and mental health; pharmacology (medical)Global Assessment of FunctioningAripiprazoleSchizoaffective disorderPharmacyOutcome Assessment (Health Care)03 medical and health sciencesYoung Adult0302 clinical medicineglobal assessment of functioningInternal medicineOutcome Assessment Health CarePaliperidone PalmitatemedicineHumansPharmacology (medical)aripiprazole monohydratearipiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Young Adult; Outcome Assessment (Health Care)Paliperidone Palmitatebusiness.industrylong-acting injectable antipsychoticsMiddle Agedschizoaffective disordermedicine.disease030227 psychiatryPsychiatry and Mental healthNeurologyPsychotic DisordersSchizophreniaDelayed-Action PreparationsSettore SECS-P/03 - Scienza delle FinanzeSchizophreniaChronic schizophreniaAripiprazoleFemaleNeurology (clinical)business030217 neurology & neurosurgeryDiagnosis of schizophreniamedicine.drugAntipsychotic AgentsHuman psychopharmacology
researchProduct

Risperidone in the Treatment of Disorders with a combined Psychotic and Depressive Syndrome - A Functional Approach

1992

In vitro receptor-binding profiles and in vivo pharmacological studies have shown risperidone to be a potent mixed serotonin-S2 dopamine-D2-like receptor antagonist. While anti-D2 activity may relate to the antipsychotic potency of neuroleptic drugs, an antidepressive efficacy of substances with anti-S2 activity has been suggested. In an open pilot-study, ten patients with schizodepressive disorders or a DSM-III-R diagnosis of psychotic major depressive episodes were treated with risperidone (2-10 mg/d) for six weeks. Weekly psychopathological evaluation was performed, including BPRS, SANS, SAPS, VAS scales, and AIMS and UKU for the assessment of side-effects. Generally, the psychotic syndr…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPiperidinesInternal medicineHumansMedicinePotencyPharmacology (medical)AntipsychoticDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressive DisorderRisperidonebusiness.industryDopamine antagonistIsoxazolesSyndromeGeneral MedicineMiddle AgedRisperidoneReceptor antagonistBiperidenPsychiatry and Mental healthPsychotic DisordersAnesthesiaFemalebusinessAntipsychotic AgentsPsychopathologymedicine.drugPharmacopsychiatry
researchProduct

Absence of tolerance in duodenal ulcer patients treated for 28 days with a bedtime dose of roxatidine or ranitidine

1996

There is much experimental work on the occurrence of tolerance to the antisecretory effect of H2-receptor antagonists in healthy subjects, while data on its development in patients with duodenal ulcer are poor and conflicting. Moreover, this phenomenon has not been studied previously with 24 h gastric pH-metry in patients with active duodenal ulcer. For these reasons, we carried out a prospective pharmacodynamic investigation in 48 patients with endoscopically proven duodenal ulcer using the well-established once daily dosing schedule of H2 blockers. They were studied by means of 24 h continuous endoluminal pH-metry which was performed before, on d1 and d28 after receiving an oral bedtime d…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentRanitidineBedtimeGastroenterologyH2 antagonistRanitidinePiperidinesHistamine H2 receptorOral administrationDrug toleranceInternal medicinemedicineHumansSingle-Blind MethodPharmacology (medical)Prospective StudiesPharmacologyAnalysis of Variancebusiness.industryDrug ToleranceGastric Acidity DeterminationHydrogen-Ion ConcentrationMiddle Agedmedicine.anatomical_structureHistamine H2 AntagonistsDuodenal UlcerPharmacodynamicsDuodenumFemalebusinessmedicine.drugFundamental & Clinical Pharmacology
researchProduct

Soothing the seizures of children.

2008

Endocannabinoids are versatile molecules, regulating a variety of functions in the body. Daniele Piomelli explores how recent clinical trials testing rimonabant, an inhibitor of endocannabinoid signaling, for weight loss emerged from studies of individuals with schizophrenia; such trials have spurred basic research into how endocannabinoids affect both energy use and mood. Beat Lutz and Krisztina Monory examine how rimonabant might prove useful for preventing the development of adult epilepsy in response to fever-induced seizures in infants and young children.

AdultModels NeurologicalGeneral Biochemistry Genetics and Molecular BiologySeizures FebrileEpilepsyRimonabantPiperidinesBasic researchWeight lossCannabinoid Receptor ModulatorsmedicineHumansCannabinoid Receptor AntagonistsClinical Trials as TopicEpilepsybusiness.industryGeneral Medicinemedicine.diseaseEndocannabinoid systemClinical trialMoodChild PreschoolCannabinoid receptor antagonistPyrazoleslipids (amino acids peptides and proteins)medicine.symptomRimonabantbusinessNeurosciencemedicine.drugNature medicine
researchProduct

Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation fo…

2005

Purpose In the era of molecular therapy of chronic myelogenous leukemia (CML) applying BCR-ABL tyrosine kinase inhibitors, the usefulness of molecular end points, in particular, quantitative polymerase chain reaction (PCR) for BCR-ABL in monitoring responses has been broadly accepted. Therefore, we have designed a prospective phase II trial in CML, which, for the first time, evaluated the feasibility and safety of molecular end points as surrogate markers to guide through a stratified treatment algorithm within a multicenter trial. Patients and Methods As a clinical model, we adopted minimal residual disease (MRD) found in relapse after allogeneic stem cell transplantation (SCT) in CML. For…

AdultOncologyCancer Researchmedicine.medical_specialtyTime FactorsMaximum Tolerated Dosemedicine.drug_classFusion Proteins bcr-ablGraft vs Host DiseaseAntineoplastic AgentsPolymerase Chain ReactionPiperazinesTyrosine-kinase inhibitorMyelogenousLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesMulticenter trialInternal medicinemedicineHumansTransplantation HomologousProspective Studiesbusiness.industryRemission InductionImatinibProtein-Tyrosine Kinasesmedicine.diseaseMinimal residual diseaseTransplantationPyrimidinesTreatment OutcomeImatinib mesylateOncologyBenzamidesImmunologyImatinib MesylateFeasibility StudiesbusinessStem Cell Transplantationmedicine.drugChronic myelogenous leukemiaJournal of Clinical Oncology
researchProduct

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid…

2008

Abstract Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML after interferon-α (IFNα) failure enrolled 532 patients, 454 with a confirmed diagnosis of CP CML. Median time from diagnosis was 34 months; median duration of imatinib treatment was 65 months. Cumulative best rates of major cytogenetic response (MCyR) and complete cytogenetic response (CCyR) were 67% and 57%, respectively. At the 5-year landmark, 184 (41%) of the 454 patients are in CCyR. At more than 6 years, 199 (44%) of the 454 patients remain on imatinib. Most responses occurred within 12 mont…

AdultOncologymedicine.medical_specialtyTime FactorsAdolescentDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classImmunologyimatinib CML interferon-alphaSalvage therapyBlastic PhaseBiochemistryPiperazinesTyrosine-kinase inhibitorhemic and lymphatic diseasesInternal medicinemedicineHumansneoplasmsSurvival rateAgedAged 80 and overSalvage Therapybusiness.industryInterferon-alphaMyeloid leukemiaImatinibCell BiologyHematologyMiddle Agedmedicine.diseaseSurgerySurvival RatePyrimidinesTreatment OutcomeImatinib mesylateBenzamidesLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylatebusinessFollow-Up StudiesChronic myelogenous leukemiamedicine.drug
researchProduct